WASHINGTON(AP) — The U.S. Food and Drug Administration is refusing to consider Moderna’s application for a new flu vaccine made with Nobel Prize-winning mRNA technology, the company announced Tuesday.
The Food and Drug Administration has reversed its decision not to review a new flu vaccine from Moderna, the pharmaceutical company said Wednesday. Last week, the FDA sent a missive to Moderna ...
The Food and Drug Administration's decision, made public on Feb. 10, to not review an application to approve Moderna's proposed mRNA-based flu vaccine set off a firestorm of criticism from public ...
FDA reversal, patent relief, and mRESVIA risks show a commoditized market and lofty $20B valuation. See more here.
The FDA is reviewing the first mRNA flu vaccine for adults 50 and older. Learn how this technology could lead to faster and more effective shots.
April 6, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Company will present late-breaking oral presentations on ...
FILE - A sign marks an entrance to a Moderna building in Cambridge, Mass., May 18, 2020. (AP Photo/Bill Sikes, File) FILE - A sign marks an entrance to a Moderna building in Cambridge, Mass., May 18, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results